Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1988 1
1992 2
1993 1
1996 1
1997 5
1998 2
1999 2
2000 1
2001 4
2002 3
2003 2
2004 3
2005 3
2006 4
2007 1
2008 4
2009 2
2010 4
2011 4
2012 5
2013 6
2014 7
2015 8
2016 4
2017 5
2018 6
2019 5
2020 9
2021 11
2022 7
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma; Children’s Oncology Group. Minard-Colin V, et al. N Engl J Med. 2020 Jun 4;382(23):2207-2219. doi: 10.1056/NEJMoa1915315. N Engl J Med. 2020. PMID: 32492302 Free PMC article. Clinical Trial.
Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis.
Luo Z, Xia M, Shi W, Zhao C, Wang J, Xin D, Dong X, Xiong Y, Zhang F, Berry K, Ogurek S, Liu X, Rao R, Xing R, Wu LMN, Cui S, Xu L, Lin Y, Ma W, Tian S, Xie Q, Zhang L, Xin M, Wang X, Yue F, Zheng H, Liu Y, Stevenson CB, de Blank P, Perentesis JP, Gilbertson RJ, Li H, Ma J, Zhou W, Taylor MD, Lu QR. Luo Z, et al. Among authors: perentesis jp. Nature. 2022 Dec;612(7941):787-794. doi: 10.1038/s41586-022-05487-2. Epub 2022 Nov 30. Nature. 2022. PMID: 36450980
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial.
Mascia AE, Daugherty EC, Zhang Y, Lee E, Xiao Z, Sertorio M, Woo J, Backus LR, McDonald JM, McCann C, Russell K, Levine L, Sharma RA, Khuntia D, Bradley JD, Simone CB 2nd, Perentesis JP, Breneman JC. Mascia AE, et al. Among authors: perentesis jp. JAMA Oncol. 2023 Jan 1;9(1):62-69. doi: 10.1001/jamaoncol.2022.5843. JAMA Oncol. 2023. PMID: 36273324 Free PMC article.
Ultra-high dose-rate proton FLASH improves tumor control.
Shukla S, Saha T, Rama N, Acharya A, Le T, Bian F, Donovan J, Tan LA, Vatner R, Kalinichenko V, Mascia A, Perentesis JP, Kalin TV. Shukla S, et al. Among authors: perentesis jp. Radiother Oncol. 2023 Sep;186:109741. doi: 10.1016/j.radonc.2023.109741. Epub 2023 Jun 12. Radiother Oncol. 2023. PMID: 37315577
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Bielack SS, et al. J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. J Clin Oncol. 2015. PMID: 26033801 Free PMC article. Clinical Trial.
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.
Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, Bolanos LC, Christie S, Smith MA, Niederkorn M, Muto T, Kesari S, Garrett-Bakelman FE, Bartholdy B, Will B, Weirauch MT, Mulloy JC, Gul Z, Medlin S, Kovall RA, Melnick AM, Perentesis JP, Greis KD, Nurmemmedov E, Seibel WL, Starczynowski DT. Barreyro L, et al. Among authors: perentesis jp. Sci Transl Med. 2022 Mar 9;14(635):eabb7695. doi: 10.1126/scitranslmed.abb7695. Epub 2022 Mar 9. Sci Transl Med. 2022. PMID: 35263148
HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.
Garrett MC, Albano R, Carnwath T, Elahi L, Behrmann CA, Pemberton M, Woo D, O'Brien E, VanCauwenbergh B, Perentesis J, Shah S, Hagan M, Kendler A, Zhao C, Paranjpe A, Roskin K, Kornblum H, Plas DR, Lu QR. Garrett MC, et al. Among authors: perentesis j. Sci Rep. 2023 Aug 1;13(1):12433. doi: 10.1038/s41598-023-33889-3. Sci Rep. 2023. PMID: 37528157 Free PMC article.
The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia.
Niederkorn M, Ishikawa C, M Hueneman K, Bartram J, Stepanchick E, R Bennett J, E Culver-Cochran A, Bolanos LC, Uible E, Choi K, Wunderlich M, Perentesis JP, M Chlon T, Filippi MD, Starczynowski DT. Niederkorn M, et al. Among authors: perentesis jp. Leukemia. 2022 Feb;36(2):438-451. doi: 10.1038/s41375-021-01394-z. Epub 2021 Aug 31. Leukemia. 2022. PMID: 34465865 Free PMC article.
In Regard to Buchsbaum et al.
Breneman J, Perentesis JP, Bradley J, Mascia A, Abel E, Sharda A, Khuntia D, Sharma RA, Simone CB 2nd. Breneman J, et al. Among authors: perentesis jp. Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1544-1545. doi: 10.1016/j.ijrobp.2021.03.034. Epub 2021 Mar 26. Int J Radiat Oncol Biol Phys. 2021. PMID: 33775856 No abstract available.
116 results